New Delhi, 21/5 (AO Bureau):Big news about Bharat Biotech’s Corona vaccine COVAXIN. The company is now going to do a clinical trial of the third dose of its vaccine. For this clinical trial, Bharat Biotech has received approval from the Subject Expert Committee of the Central Drug Standard Controller Organization and its clinical trial is going to start soon at AIIMS Hospital in Delhi. On this, ABP News spoke to Dr. Sanjay Rai, Principal Investigator of clinical trial of this vaccine in AIIMS.
What will be gained from the third dose trial and why are these trials happening?
In the original clinical trial, phase 1, 2 and 3, two doses were given at a interval of four weeks. After that it was found that the vaccine is safe and effective. The government also launched it. There is still a need to generate a little evidence that if after 6 months the immunity is decreasing, then by giving the third dose, it will increase. What can his protected affixes increase? For this, this process is being adopted to generate evidence. May be the immunity is good after giving the third dose, it may not have any effect. The amount of immunity that you are protecting first, be it now. Generating evidences after giving third dose.
Who will join this trial?
This is not for newcomers, there is a demand for cocaine. People start coming, we are not taking new people in it. This will include only those who have joined the trial.
At what intervals will this dose be given?
Two doses have been given to them, first dose will be given to them.